VaxSyna, Inc.
Biotechnology company developing a modular vaccine platform that forms higher-order antibody complexes by fusing human IgG to target antigens and an epitope tag to enable multivalent antigen display and Fc-receptor crosslinking. The platform is used to create prophylactic and therapeutic vaccine candidates and is manufactured using a transient, plant-based expression system in Nicotiana benthamiana with a geminiviral vector for rapid, high-yield recombinant protein production.
Industries
N/A
Products
HerpeVax (Herpes simplex virus vaccine candidate)
A vaccine candidate based on an antibody–antigen immune complex platform designed to target HSV antigens, reported in preclinical studies to elicit neutralizing antibody responses against HSV-1 and HSV-2.
HerpeVax (Herpes simplex virus vaccine candidate)
A vaccine candidate based on an antibody–antigen immune complex platform designed to target HSV antigens, reported in preclinical studies to elicit neutralizing antibody responses against HSV-1 and HSV-2.
Expertise Areas
- Vaccine platform engineering
- Antibody fusion protein design
- Plant-based biomanufacturing (transient expression)
- Preclinical vaccine development and immunogenicity testing
Key Technologies
- Antibody fusion proteins
- Self-assembling immune complexes
- Multivalent antigen display
- Virus-like particles